A5063035674- CAR-T cell therapy research
- Viral Infectious Diseases and Gene Expression in Insects
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Biosimilars and Bioanalytical Methods
- Nanowire Synthesis and Applications
- Chronic Lymphocytic Leukemia Research
- CRISPR and Genetic Engineering
- Liver Diseases and Immunity
- Drug Transport and Resistance Mechanisms
- Neuroendocrine Tumor Research Advances
- Virus-based gene therapy research
- Advancements in Semiconductor Devices and Circuit Design
- Organ Transplantation Techniques and Outcomes
- Hematopoietic Stem Cell Transplantation
- Renal Transplantation Outcomes and Treatments
Donostiako Unibertsitate Ospitalea
2024
Navarre Institute of Health Research
2021-2023
Biogipuzkoa Health Research Institute
2023
Complejo Hospitalario de Navarra
2020-2021
Identification of new markers associated with long-term efficacy in patients treated CAR T cells is a current medical need, particularly diseases such as multiple myeloma. In this study, we address the impact density on functionality BCMA cells. Functional and transcriptional studies demonstrate that high expression construct show an increased tonic signaling up-regulation exhaustion vitro cytotoxicity but decrease vivo BM infiltration. Characterization gene regulatory networks using...
Despite the potential of CAR-T therapies for hematological malignancies, their efficacy in patients with relapse and refractory Acute Myeloid Leukemia has been limited. The aim our study to develop manufacture a cell product that addresses some current limitations. We initially compared phenotype T cells from AML healthy young elderly controls. This analysis showed displayed predominantly effector phenotype, increased expression activation (CD69 HLA-DR) exhaustion markers (PD1 LAG3),...
We report a case based on simultaneous occurrence of Waldenström macroglobulinemia, myeloma and amyloidosis as collision neoplasm. The strangeness severity the presented diagnostic therapeutic challenge, which required individualised treatment close follow-up to achieved stringent complete response.
ABSTRACT Identification of new markers associated with long-term efficacy in patients treated CAR T cells is a current medical need, particularly diseases such as multiple myeloma. In this study we address the impact density on functionality BCMA-CAR cells. Functional and transcriptional studies demonstrate that high expression construct show an increased tonic signaling upregulation exhaustion markers, vitro cytotoxicity but decrease vivo BM infiltration. Characterization Gene Regulatory...
<h3>Background</h3> Multiple myeloma (MM) remains an incurable disease despite advances in the development of new therapies. Currently, immune therapies based on chimeric antigen receptor-modified T lymphocytes (CAR-T therapies) targeting B-lymphocyte maturation (BCMA) has revolutionized treatment MM. However, most patients continue to relapse, and this lack long-term response calls for further improvement these The main objective work is develop CAR designs by combining humanized scFv that...
Cell therapy utilizing chimeric antigen receptors (CARs) in conjunction with immune cells, primarily T lymphocytes, is known as CAR-T cell therapy. This innovative approach revolutionizing the landscape of oncohaematology by precisely targeting specific antigens for elimination. However, despite its promising prospects, presents several challenges, including a notable rate disease relapse, intricate pathologies impeding widespread adoption, prolonged manufacturing timelines, and substantial...
We report a case based on simultaneous occurrence of Waldenström macroglobulinemia, myeloma and amyloidosis as collision neoplasm. The strangeness severity the presented diagnostic therapeutic challenge, which required individualised treatment close follow-up to achieved stringent complete response.